UFP Technologies (UFPT) just paired its Q1 2026 earnings with a clear push on acquisitions, as management highlighted a full deal pipeline, ongoing bids, and a disciplined filter on price, culture, and fit.

The Q1 2026 earnings update and acquisition commentary have arrived alongside a sharp swing in sentiment, with a 19.7% 7 day share price return and a 14.6% 30 day share price return partly offsetting a 13.8% 90 day decline and leaving the 1 year total shareholder return slightly down despite a strong multi year gain. Recent strength suggests momentum is rebuilding as investors reassess growth potential in medical markets and the company’s active, but disciplined, M&A pipeline.

If earnings driven moves like UFPT’s have your attention, it can be a useful moment to widen your hunt for quality operators and check out 19 top founder-led companies

With UFPT trading at US$230.55 and sitting at a sizeable discount to both analyst targets and some intrinsic estimates, the key question is whether that gap reflects mispricing or whether the stock already fully reflects the growth story.

Price-to-Earnings of 25.9x: Is it justified?

UFP Technologies closed at $230.55 and sits on a P/E of 25.9x, which leaves the stock looking expensive compared to both its peers and an estimated fair multiple.

The P/E multiple compares the share price to earnings per share, giving a quick read on how much investors are paying for current profits. For a medical equipment stock with established earnings, it is a common yardstick because it reflects what the market is willing to pay today for each dollar of profit.

For UFPT, the current 25.9x P/E is above the peer group average of 24.8x and above the US Medical Equipment industry average of 24.1x, so investors are paying a premium to the sector. It is also higher than the estimated fair P/E of 22.9x. This points to a level the market could potentially move toward if sentiment or growth expectations cool.

Result: Price-to-Earnings of 25.9x (OVERVALUED)

However, there are clear pressure points, including UFPT’s premium P/E relative to peers and the risk that acquisition driven expansion does not translate into sustained earnings power.

Another View: Cash Flows Point to Undervaluation

While the current 25.9x P/E makes UFPT look expensive compared with peers and a fair ratio of 22.9x, the SWS DCF model points in the opposite direction. On that cash flow view, the stock at $230.55 sits about 35.5% below an estimated value of $357.19. This frames today’s price as a possible opportunity rather than pure premium. The question is which lens to rely on more over a longer investment horizon.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out UFP Technologies for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 50 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment clearly split between premium multiples and potential undervaluation, it helps to move fast, test the numbers yourself, and decide where you stand. To see what is currently exciting investors, take a closer look at the company's 3 key rewards

Looking for more investment ideas?

If UFPT is on the watchlist, now is the moment to widen the search, compare set ups, and spot opportunities that might slip past less prepared investors.

• Target resilient income by reviewing companies that appear in the 12 dividend fortresses.
• Hunt for mispriced potential with the screener containing 21 high quality undiscovered gems and see which stories the market might be overlooking.
• Prioritize capital preservation by checking stocks highlighted in the 71 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.